Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction

BACKGROUND: Sorafenib is the only FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). In clinical practice, dose reductions are often required, although there are limited efficacy data related to dose modifications. Given the prevalence of HCC in South Texas, we assessed the e...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Gastrointest Oncol
Main Authors: Al-Rajabi, Raed, Patel, Sukeshi, Ketchum, Norma S., Jaime, Nicole A., Lu, Ting-Wei, Pollock, Brad H., Mahalingam, Devalingam
Format: Artigo
Sprog:Inglês
Udgivet: AME Publishing Company 2015
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4397242/
https://ncbi.nlm.nih.gov/pubmed/26029452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2015.005
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker